Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
10
08
2022
pubmed:
25
9
2022
medline:
26
11
2022
entrez:
24
9
2022
Statut:
ppublish
Résumé
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) in the Phase 3b CompLEEment-1 trial. To evaluate the safety and efficacy of ribociclib plus letrozole in the Italian subpopulation with HR+, HER2- ABC from the CompLEEment-1 trial. Patients with HR+, HER2- ABC received ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day) while men and premenopausal women additionally received goserelin. Patients were allowed with ≤ 1 line of prior chemotherapy and an Eastern Cooperative Oncology Group performance status of ≤ 2. The primary outcome included safety and tolerability. Of the 554 Italian patients, 246 (44.4 %) patients completed treatment. The reasons for treatment discontinuation included progressive disease (PD; 36.6 %), adverse events (AEs; 11.9 %), and death (1.6 %). All-grade AEs and grade ≥ 3 AEs occurred in 98.9 % and 77.8 % patients, respectively. The most common treatment-related AEs were neutropenia (73.6 %), followed by leukopenia (32.1 %), and nausea (25.3 %). The overall response rate was 28.2 % (95 % confidence interval [CI], 24.4-32.1); clinical benefit rate was 71.7 % (95 % CI, 67.7-75.4); and median time to progression was 26.7 months (95 % CI, 24.8-non-estimable). Health-related quality of life scores were maintained during treatment. The safety and efficacy profiles of ribociclib plus letrozole in the Italian subpopulation was found to be consistent with the CompLEEment-1 global population result, MONALEESA-2, and MONALEESA-7 outcomes, which reaffirm ribociclib plus letrozole as the frontline treatment option in patients with HR+, HER2- ABC. NCT02941926 (30 November 2016).
Sections du résumé
BACKGROUND
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) in the Phase 3b CompLEEment-1 trial.
OBJECTIVE
To evaluate the safety and efficacy of ribociclib plus letrozole in the Italian subpopulation with HR+, HER2- ABC from the CompLEEment-1 trial.
PATIENTS AND METHODS
Patients with HR+, HER2- ABC received ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day) while men and premenopausal women additionally received goserelin. Patients were allowed with ≤ 1 line of prior chemotherapy and an Eastern Cooperative Oncology Group performance status of ≤ 2. The primary outcome included safety and tolerability.
RESULTS
Of the 554 Italian patients, 246 (44.4 %) patients completed treatment. The reasons for treatment discontinuation included progressive disease (PD; 36.6 %), adverse events (AEs; 11.9 %), and death (1.6 %). All-grade AEs and grade ≥ 3 AEs occurred in 98.9 % and 77.8 % patients, respectively. The most common treatment-related AEs were neutropenia (73.6 %), followed by leukopenia (32.1 %), and nausea (25.3 %). The overall response rate was 28.2 % (95 % confidence interval [CI], 24.4-32.1); clinical benefit rate was 71.7 % (95 % CI, 67.7-75.4); and median time to progression was 26.7 months (95 % CI, 24.8-non-estimable). Health-related quality of life scores were maintained during treatment.
CONCLUSION
The safety and efficacy profiles of ribociclib plus letrozole in the Italian subpopulation was found to be consistent with the CompLEEment-1 global population result, MONALEESA-2, and MONALEESA-7 outcomes, which reaffirm ribociclib plus letrozole as the frontline treatment option in patients with HR+, HER2- ABC.
TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION
NCT02941926 (30 November 2016).
Identifiants
pubmed: 36152144
doi: 10.1007/s11523-022-00913-x
pii: 10.1007/s11523-022-00913-x
pmc: PMC9684264
doi:
Substances chimiques
Letrozole
7LKK855W8I
ribociclib
TK8ERE8P56
Receptors, Progesterone
0
Receptor, ErbB-2
EC 2.7.10.1
Receptors, Estrogen
0
Banques de données
ClinicalTrials.gov
['NCT02941926']
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-625Informations de copyright
© 2022. The Author(s).
Références
Arnesen S, Blanchard Z, Williams MM, Berrett KC, Li Z, Oesterreich S, et al. Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects. Can Res. 2021;81(3):539–51.
doi: 10.1158/0008-5472.CAN-20-1171
Burris HA 3rd. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Expert Rev Anticancer Ther. 2018;18(3):201–13.
doi: 10.1080/14737140.2018.1435275
pubmed: 29457921
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.
doi: 10.1056/NEJMoa1109653
pubmed: 22149876
Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(7):1979–87.
doi: 10.1158/1078-0432.CCR-09-1823
pubmed: 20332324
Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006;98(18):1285–91.
doi: 10.1093/jnci/djj357
pubmed: 16985247
Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431–42.
doi: 10.1056/NEJMra023246
pubmed: 12802030
Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist. 2004;9(5):489–96.
doi: 10.1634/theoncologist.9-5-489
pubmed: 15477633
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a Phase 1II trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.
doi: 10.1093/annonc/mdy155
pubmed: 29718092
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16.
doi: 10.1056/NEJMoa1903765
pubmed: 31166679
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised Phase 3 trial. Lancet Oncol. 2018;19(7):904–15.
doi: 10.1016/S1470-2045(18)30292-4
pubmed: 29804902
Yardley DA, Hart L, Favret A, Blau S, Diab S, Richards D, et al. Efficacy and safety of Ribociclib with Letrozole in US patients enrolled in the MONALEESA-2 study. Clin Breast Cancer. 2019;19(4):268–77.
doi: 10.1016/j.clbc.2019.02.007
pubmed: 31160171
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the Phase 1II randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015–24.
doi: 10.1016/j.annonc.2021.05.353
pubmed: 34102253
Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a Phase 1II randomized clinical trial. Clin Cancer Res. 2022;28(5):851–9.
doi: 10.1158/1078-0432.CCR-21-3032
pubmed: 34965945
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50.
doi: 10.1056/NEJMoa2114663
pubmed: 35263519
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, et al. Full population results from the core Phase of CompLEEment-1, a Phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast cancer research and treatment. Breast Cancer Res Treat. 2021;189(3):689-699.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.
doi: 10.1056/NEJMoa1607303
pubmed: 27959613
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.
doi: 10.1038/s41523-018-0097-z
pubmed: 30675515
pmcid: 6336880
De Laurentiis M, Puglisi F, Del Mastro L, Colleoni M, Montemurro F, Bianchi G, et al. Efficacy and safety of first-line Ribociclib (RIB) combined with Letrozole (LET) in postmenopausal patients with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC): Results from Phase IIIb BioItaLEE study. Associazione Italiana di Oncologia Medica 2021; Italy.
Krohe M, Hao Y, Lamoureux RE, Galipeau N, Globe D, Foley C, et al. Patient-reported outcomes in metastatic breast cancer: a review of industry-sponsored clinical trials. Breast Cancer Basic Clin Res. 2016;10:93–102.
doi: 10.4137/BCBCR.S39385
Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat. 2018;170(3):535–45.
doi: 10.1007/s10549-018-4769-z
pubmed: 29654415
pmcid: 6022531